Drug-eluting stents for cardiovascular disorders.
Drug-eluting stents have emerged in recent years as a very promising therapy for prevention of restenosis after coronary implantation. Early randomized, clinical trials have suggested that stents eluting drugs, such as paclitaxel or sirolimus, released from polymeric and nonpolymeric coatings, are able to reduce restenosis in simple de novo lesions by more than 80% in comparison with bare metal stents. If restenosis can be indeed minimized globally by drug-eluting stents, coronary revascularization may expand to patients and lesions currently not considered for percutaneous intervention because of excessive recurrence, and may open possibilities for other stent-based endovascular treatments of atherosclerosis.
Granada
Juan F
JF
The Methodist DeBakey Heart Center, Baylor College of Medicine, 6535 Fannin, Room FB 1034, Houston, TX 77030, USA.
Kaluza
Grzegorz L
GL
Raizner
Albert
A
D002318:Cardiovascular Diseases / Q000188:drug therapy*; D023903:Coronary Restenosis / Q000209:etiology; D016503:Drug Delivery Systems; D006801:Humans; D011108:Polymers; D011474:Prosthesis Design; D015607:Stents / Q000009:adverse effects
D011108:Polymers